> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-07-12 06:09 KST **Entry ID:** 40 **Tags:** #PHOX2B #Phox2b #CRISPR/Cas9 knock-out #CRISPR knockout #functional genomics #IMR32 #neuroblastoma #neuroblastoma cell line #MYCN #MYCN amplification #ALK #ALK mutation --- ## 🔬 Today's Top Findings ### 1. CRISPR/Cas9 PHOX2B functional knock-out in IMR32 neuroblastoma cells impairs neuronal excitability via ion-channel dysregulation (GSE330047, score 9, n=13, Homo sapiens, pdat 2026/07/10 = 2 days ago, freshest score-9 spatial hit this cycle) ### 2. Type I interferon-activated myeloid states are associated with less fibrotic stages in idiopathic pulmonary fibrosis (GSE292589, score 9, n=4, Homo sapiens, single-cell + spatial, pdat 2026/07/10 = 2 days ago) ### 3. Iron-catalyzed oxidative stress reveals an exposome-related ferroptosis-resistant karyomegalic niche in BRCA1-linked renal carcinogenesis (GSE338104, score 7, n=6, Rattus norvegicus, single-cell + spatial, pdat 2026/07/10 = 2 days ago, freshest score-7 ferroptosis-renal deposit this cycle) ## 📋 Synthesis Three freshly surfaced, novel Brown Biotech signals from the 2026-07-12 06:00 KST watcher scan (105 hits collected_at 2026-07-11 21:01-21:02 UTC; all three primary signals are novel versus yesterday's id:39 digest and absent from the last five sampleDigests). (1) CRISPR/Cas9 PHOX2B functional knock-out in IMR32 neuroblastoma cells impairs neuronal excitability via ion-channel dysregulation (GSE330047, n=13 Homo sapiens spatial, pdat 2026/07/10 = 2 days ago, the freshest score-9 spatial perturbation hit this cycle and a direct refractory-cancer + neuroblastoma + pediatric-oncology input for Brown Biotech's refractory-cancer lane where neuroblastoma is the most-common extracranial solid tumor of childhood, accounts for ~7-10% of all pediatric cancers and ~15% of pediatric cancer deaths, and remains incurable in ~50% of high-risk cases with 5-year event-free survival <50% for MYCN-amplified + high-risk disease). (2) Type I interferon-activated myeloid states are associated with less fibrotic stages in idiopathic pulmonary fibrosis (GSE292589, n=4 Homo sapiens single-cell + spatial, pdat 2026/07/10 = 2 days ago, the freshest score-9 IPF-immune-microenvironment hit this cycle and a direct bioinformatics + fibrosis / IPF / immunology-of-fibrosis input for Brown Biotech's fibrosis / IPF lane where IPF is the most-lethal chronic fibrosing interstitial lung disease with median survival 3-5 years from diagnosis, only two approved disease-modifying therapies (pirfenidone + nintedanib) that slow but do not halt progression, and a critical unmet need for immune-modulating + myeloid-reprogramming therapeutics). (3) Iron-catalyzed oxidative stress reveals an exposome-related ferroptosis-resistant karyomegalic niche in BRCA1-linked renal carcinogenesis (GSE338104, n=6 Rattus norvegicus single-cell + spatial, pdat 2026/07/10 = 2 days ago, the freshest score-7 ferroptosis + renal-carcinogenesis + BRCA1-axis deposit this cycle and a direct longevity / anti-aging / ferroptosis-target-nomination / renal-aging input for Brown Biotech's longevity + ferroptosis + renal lane where ferroptosis-resistance + BRCA1-driven DNA-damage-response defects + karyomegalic-cell-niche biology are emerging as a tractable axis for combination ferroptosis-inducer + PARP-inhibitor therapy in BRCA1-mutant cancers including breast + ovarian + prostate + pancreatic + renal). --- ## 🎯 Highlights ### 1. CRISPR/Cas9 PHOX2B functional knock-out in IMR32 neuroblastoma cells impairs neuronal excitability via ion-channel dysregulation (GSE330047, score 9, n=13, pdat 2026/07/10 = 2 days ago, spatial, Homo sapiens, clean license, raw files available, suppfile TXT): the FRESHEST score-9 spatial perturbation hit in the entire 2026-07-12 scan and a direct bioinformatics + refractory-cancer + neuroblastoma + pediatric-oncology input for Brown Biotech's refractory-cancer lane; PHOX2B (Paired Mesoderm Homeobox 2B, the canonical neural-crest-derived sympathetic-nervous-system transcription factor that drives terminal differentiation of sympathetic neurons + chromaffin cells of the adrenal medulla) is the master regulator of sympathetic-nervous-system development and is required for the noradrenergic phenotype of neuroblastoma + pheochromocytoma + paraganglioma + Hirschsprung-disease-associated-enteric-nervous-system development; PHOX2B is a lineage-survival oncogene in neuroblastoma (frequently co-amplified with MYCN in high-risk disease, with germline PHOX2B mutations causing congenital central hypoventilation syndrome [CCHS / Ondine's curse] and predisposing to neuroblastoma + Hirschsprung-disease + peripheral-neuroblastic-tumors); IMR32 is the canonical human neuroblastoma cell line (Homo sapiens, MYCN-amplified, ALK-mutant, established from a 1-year-old boy's neuroblastoma abdominal mass in 1967, widely used as the reference neuroblastoma model); CRISPR/Cas9 PHOX2B functional knock-out in IMR32 followed by spatial transcriptomic dissection of the resulting neuronal-excitability phenotype delivers direct dissection of (a) ion-channel transcriptional dysregulation including SCN1A/SCN2A/SCN3A/SCN8A/SCN9A voltage-gated sodium channels, KCNA1/KCNA2/KCNQ2/KCNQ3 voltage-gated potassium channels, CACNA1A/CACNA1G voltage-gated calcium channels, and the entire neuronal-firing machinery, (b) sympathetic-neuron-vs-neuroblastoma-state transition mapping (neuroblastoma cells are arrested sympathetic-neuron precursors that retain ion-channel expression and electrophysiological activity), (c) ALK/MYCN/PHOX2B-axis dissection including PHOX2B-as-upstream-of-MYCN + PHOX2B-as-upstream-of-ALK relationships, and (d) neuroblastoma-differentiation-therapy candidate nomination (retinoic-acid-induced differentiation + PHOX2B-modulating compounds as canonical differentiation-therapy strategies); the n=13 design enables paired-control + PHOX2B-KO spatial dissection with sufficient statistical power for cell-state-deconvolution + ion-channel-program identification; direct BB refractory-cancer + neuroblastoma + pediatric-oncology + ALK/MYCN/PHOX2B-axis lane input pairing with the canonical differentiation-therapy landscape (retinoic-acid + 13-cis-retinoic-acid + isotretinoin in maintenance therapy for high-risk neuroblastoma) and emerging ALK-inhibitor landscape (crizotinib + ceritinib + lorlatinib + PF-06463922 for ALK-mutant neuroblastoma). ### 2. Type I interferon-activated myeloid states are associated with less fibrotic stages in idiopathic pulmonary fibrosis (GSE292589, score 9, n=4, pdat 2026/07/10 = 2 days ago, single-cell + spatial, Homo sapiens, clean license, raw files available, suppfile TAR): the FRESHEST score-9 IPF-immune-microenvironment hit in the entire 2026-07-12 scan and a direct bioinformatics + fibrosis / IPF / immunology-of-fibrosis input for Brown Biotech's fibrosis / IPF lane; idiopathic pulmonary fibrosis (IPF) is the most-lethal chronic fibrosing interstitial lung disease (median survival 3-5 years from diagnosis, ~3M affected globally, prevalence ~20 per 100,000 in the US with rising incidence in older adults), with only two approved disease-modifying therapies (pirfenidone [a small-molecule TGF-beta + collagen-synthesis + fibroblast-proliferation inhibitor] + nintedanib [a triple angiokinase inhibitor targeting VEGFR + FGFR + PDGFR]) that slow but do not halt disease progression and a critical unmet need for immune-modulating + myeloid-reprogramming therapeutics; the canonical IPF-pathogenesis model posits alveolar-epithelial-cell (AEC) injury + senescence as the inciting event, followed by aberrant fibroblast + myofibroblast activation, ECM deposition, and progressive fibrosis — but the immune-microenvironment contribution has been increasingly recognized with myeloid cells (alveolar macrophages, monocyte-derived macrophages, monocytes, dendritic cells) playing pivotal roles in either pro-fibrotic or anti-fibrotic polarization; Type I interferon (IFN-I, including IFN-alpha + IFN-beta + IFN-epsilon + IFN-kappa + IFN-omega, signaling through IFNAR1/IFNAR2 → TYK2/JAK1 → STAT1/STAT2/IRF9 → ISGF3 → ISG transcriptional program) is the canonical antiviral + anti-proliferative + immunomodulatory cytokine axis that is suppressed in IPF (consistent with the emerging observation that IPF lungs show impaired IFN-I responses, contributing to failure of anti-fibrotic immune-surveillance); the n=4 single-cell + spatial design delivers direct dissection of (a) IFN-I-activated myeloid states across less-fibrotic vs more-fibrotic IPF stages (the central finding of the paper), (b) ISG-high vs ISG-low macrophage polarization programs with downstream fibroblast-activation impact, (c) alveolar-macrophage + monocyte-derived-macrophage + tissue-resident-macrophage subset dissection including MERTK+ tissue-resident macrophages + CCL18+ M2-like pro-fibrotic macrophages + IFN-I-activated anti-fibrotic macrophages, and (d) the spatial-cellular-niche architecture of IFN-I-activated myeloid cells within the fibrotic niche; direct BB fibrosis / IPF / immunology-of-fibrosis / myeloid-reprogramming lane input pairing with the canonical IFN-I-targeted-therapy landscape (IFN-gamma-1b [interferon gamma-1b, an IFN-gamma/IFN-II axis modulator that has been trialed in IPF with mixed results] + recombinant IFN-beta-1a + emerging IFN-I-pathway-restoration strategies + JAK-STAT inhibitors [JAK1/TYK2 inhibitors like baricitinib + ruxolitinib that modulate IFN-I signaling]). ### 3. Iron-catalyzed oxidative stress reveals an exposome-related ferroptosis-resistant karyomegalic niche in BRCA1-linked renal carcinogenesis (GSE338104, score 7, n=6, pdat 2026/07/10 = 2 days ago, single-cell + spatial, Rattus norvegicus, clean license, raw files available, suppfile H5/PARQUET/TIFF): the FRESHEST score-7 ferroptosis + renal-carcinogenesis + BRCA1-axis deposit in the entire 2026-07-12 scan and a direct longevity + ferroptosis + renal-aging + BRCA1-axis input for Brown Biotech's longevity / ferroptosis / renal-aging lane; ferroptosis is an iron-dependent regulated cell death modality (Stockwell-lab-defined, characterized by lipid peroxidation of PUFA-containing phospholipids, controlled by the GPX4 [glutathione peroxidase 4] + SLC7A11/xCT [cystine/glutamate antiporter] + ACSL4 [acyl-CoA synthetase long-chain family member 4] axis, and morphologically distinct from apoptosis + necrosis + pyroptosis + necroptosis with characteristic mitochondrial shrinkage + cristae loss + increased membrane density); BRCA1 (Breast Cancer susceptibility gene 1, the canonical tumor suppressor + DNA-damage-response + homologous-recombination-repair gene on chromosome 17q21) loss-of-function creates a homologous-recombination-deficient (HRD) state that sensitizes cells to PARP inhibitors via synthetic lethality (olaparib + talazoparib FDA-approved for BRCA1/2-mutant breast + ovarian + prostate + pancreatic cancer); however, BRCA1-deficient cells also exhibit iron-handling dysregulation + ferroptosis-sensitivity heterogeneity that creates a niche of ferroptosis-resistant karyomegalic cells (karyomegaly = enlarged hyperchromatic nuclei, a cellular-stress + aging + pre-neoplastic phenotype observed in chronic-kidney-disease + aristolochic-acid-nephropathy + post-HBV/HCV cirrhosis + BRCA1-driven cancers); the n=6 Rattus norvegicus single-cell + spatial design delivers direct dissection of (a) the karyomegalic-cell-niche cellular composition + spatial architecture in BRCA1-linked renal carcinogenesis, (b) ferroptosis-resistance vs ferroptosis-sensitivity spectrum across BRCA1-mutant cell populations (with ferroptosis-resistant karyomegalic cells potentially serving as a treatment-resistant reservoir), (c) iron-catalyzed oxidative stress (Fenton-reaction-mediated hydroxyl-radical generation) as the driver of ferroptosis-resistance evolution, and (d) exposome-related environmental-modifier dissection (dietary-iron + alcohol + aristolochic-acid + aristolochic-acid-containing-herbal-medicine exposure); direct BB longevity + ferroptosis + renal-aging + BRCA1-axis lane input pairing with the canonical ferroptosis-inducer landscape (erastin + RSL3 + IKE [imidazole-ketone-erastin] + FIN56 + ML162 + GPX4-targeting PROTACs + DHODH-inhibitor brequinar as indirect ferroptosis-inducer) and the canonical PARP-inhibitor + ferroptosis-inducer combination-therapy landscape for BRCA1/2-mutant cancers. ### 4. Combined signal: bioinformatics / refractory-cancer / neuroblastoma + pediatric-oncology (GSE330047, score 9, n=13 Homo sapiens spatial, pdat 2026/07/10 = 2 days ago, the freshest score-9 spatial perturbation hit this cycle, CRISPR/Cas9 PHOX2B knock-out in IMR32 neuroblastoma cells reveals ion-channel dysregulation as a tractable differentiation-therapy + ALK/MYCN/PHOX2B-axis dissection, direct BB refractory-cancer + neuroblastoma + pediatric-oncology lane input) + bioinformatics / fibrosis / IPF / immunology-of-fibrosis (GSE292589, score 9, n=4 Homo sapiens single-cell + spatial, pdat 2026/07/10 = 2 days ago, the freshest score-9 IPF-immune-microenvironment hit this cycle, IFN-I-activated myeloid states as anti-fibrotic + myeloid-reprogramming therapeutic target nomination, direct BB fibrosis / IPF / immunology-of-fibrosis lane input) + longevity / ferroptosis / renal-aging / BRCA1-axis (GSE338104, score 7, n=6 Rattus norvegicus single-cell + spatial, pdat 2026/07/10 = 2 days ago, the freshest score-7 ferroptosis + renal-carcinogenesis + BRCA1-axis deposit this cycle, iron-catalyzed oxidative stress + ferroptosis-resistant karyomegalic-cell-niche in BRCA1-linked renal carcinogenesis as combination ferroptosis-inducer + PARP-inhibitor therapy nomination, direct BB longevity + ferroptosis + renal-aging + BRCA1-axis lane input) — three orthogonal modalities spanning 3 of 6 Brown Biotech coverage categories (bioinformatics + longevity + clinical) with ALL THREE primary signals featuring identical pdat=2026/07/10 = 2 days ago (an unusually synchronized fresh-pdat day for the watcher), ALL THREE NOVEL versus yesterday's id:39 digest (GSE329811 + GSE300742 + GSE337307) and absent from the last five sampleDigests (id:35-id:39); the watcher's 2026-07-12 scan (collected_at 2026-07-11 21:01-21:02 UTC = 2026-07-12 06:01-06:02 KST) ran on its normal 06:00 KST cadence and emitted 105 hits with 15 score-9 entries split between 11 already-featured (GSE277080 / GSE308147 / GSE308148 / GSE281463 / GSE281464 / GSE281465 / GSE328275 / GSE337336 / GSE311507 / GSE331144) and 4 truly novel (GSE330047 + GSE292589 + GSE328422 + GSE326226); today's three primary picks emphasize the freshest unduplicated pdat=2-days-ago high-scored hits spanning refractory-cancer + fibrosis + longevity with explicit BB lane-relevance (neuroblastoma + IPF + ferroptosis-renal), each follow-up-able with Multi-Omics / AI Drug Discovery / Longevity handoff briefs on the Brown Biotech platform. --- ## 💼 Next Steps - **[Request bioinformatics / PHOX2B neuroblastoma ion-channel brief](https://brownbio.tech/multiomics#brief)** - **[Request bioinformatics / IFN-I IPF myeloid-state brief](https://brownbio.tech/multiomics#brief)** - **[Request longevity / BRCA1 ferroptosis-renal niche brief](https://brownbio.tech/services/biostatx#brief)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-07-12 06:09 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-07-12
PubMed/GEO scan · research-watcher · 06:00 KST